Abstract |
Treatment with ipilimumab, a monoclonal antibody that antagonizes cytotoxic T-lymphocyte antigen-4 (CTLA-4), results in improved survival of patients with stage IIIc-IV melanoma. However, there is a lack of data on the efficacy of ipilimumab in patients with brain metastases. To evaluate the efficacy of ipilimumab for the treatment of brain metastasis in melanoma, a multicentre, retrospective analysis of 38 patients with brain metastases in melanoma, treated with ipilimumab in the context of the French Expanded Access Program, was performed. Three patients had a 3 partial response, 5 stable disease, 15 disease progression and 15 patients died during the induction phase due to disease progression. Median overall survival was 101 days (range 54-154). The brain metastases control rate was 16% (6/38). Ipilimumab may be effective in a few patients with central nervous system metastasis. However, patients with brain metastases and a low life expectancy may not benefit sufficiently from treatment with ipilimumab.
|
Authors | Maria-Polina Konstantinou, Caroline Dutriaux, Caroline Gaudy-Marqueste, Laurent Mortier, Christophe Bedane, Céline Girard, Sophie Thellier, Thomas Jouary, Jean-Jacques Grob, Marie-Aleth Richard, Caroline Templier, Lilia Sakji, Bernard Guillot, Carle Paul, Nicolas Meyer |
Journal | Acta dermato-venereologica
(Acta Derm Venereol)
Vol. 94
Issue 1
Pg. 45-9
(Jan 2014)
ISSN: 1651-2057 [Electronic] Sweden |
PMID | 23824275
(Publication Type: Journal Article, Multicenter Study)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Ipilimumab
|
Topics |
- Antibodies, Monoclonal
(adverse effects, therapeutic use)
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Brain Neoplasms
(drug therapy, secondary)
- Disease Progression
- Female
- Humans
- Ipilimumab
- Kaplan-Meier Estimate
- Male
- Melanoma
(drug therapy, secondary)
- Retrospective Studies
- Skin Neoplasms
(pathology)
- Treatment Outcome
|